LeMaitre Vascular Stock (NASDAQ:LMAT), Trade Ideas

LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Analyst Color

Equities

News

Health Care

Price Target

Initiation

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

LMAT

Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating and a 

Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating

Pre-Market Outlook

DASH

EXTR

MTCH

PYPL

SHOP

STAA


	Needham raised the price target for  Extreme Networks, Inc.  (NASDAQ: EXTR) from $30 to $35. Needham analyst Alex Henderson maintained a Buy rating. Extreme Networks shares fell 1.7% to $29.70 in pre-market trading.


Yum! Brands To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Thursday

Penny Stocks

Movers

ALRM

AMZN

BBBY

CRCT

NEXA

NMRK

UFCS

XPEV

ZLAB

U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 800 points. Here is the list of some big stocks recording losses in the previous session.

Weibo, XPeng, Li Auto And Other Big Losers From Friday

LeMaitre Vascular Inc

A large exercise of company stock options by George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) was disclosed in a new SEC filing on March 26, as part of an insider exercise.
What Happened: LeMaitre, Chairman and CEO at LeMaitre Vascular, exercised stock options for 14,808 shares of LMAT stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924009454//Archives/edgar/data/1158895/000143774924009454/0001437749-24-009454-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The exercise price of the options was $47.93 per share.
The latest update on Wednesday morning shows LeMaitre Vascular shares down by 0.0%, trading at $65.9. At this price, LeMaitre's 14,808 shares are worth $266,154.
<h3>All You Need to Know About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>Key Indicators: LeMaitre Vascular's Financial Health</h3>
Revenue Growth: LeMaitre Vascular's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 19.36%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 68.05%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.38.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: LeMaitre Vascular's current Price to Earnings (P/E) ratio of 49.09 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 7.62, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 28.24, LeMaitre Vascular demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>The Insider's Guide to Important Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Engaging In Options Activity, George LeMaitre Exercises Options Valued At $266K In LeMaitre Vascular

It was reported on March 5, that George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) executed a significant insider sell, according to an SEC filing.
What Happened: LeMaitre's recent move involves selling 101,478 shares of LeMaitre Vascular. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924006521//Archives/edgar/data/1158895/000143774924006521/0001437749-24-006521-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value is $6,944,096.
In the Tuesday's morning session, LeMaitre Vascular's shares are currently trading at $67.92, experiencing a down of 0.0%.
<h3>Unveiling the Story Behind LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
Revenue Growth: Over the 3 months period, LeMaitre Vascular showcased positive performance, achieving a revenue growth rate of 3.1% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 68.05%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS is below the industry average. The company faced challenges with a current EPS of 0.38. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: LeMaitre Vascular's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 50.7.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 7.87 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): LeMaitre Vascular's EV/EBITDA ratio of 29.12 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Transaction: George LeMaitre Sells $6.94M Worth Of LeMaitre Vascular Shares

On March 5, it was revealed in an SEC filing that Joseph Pellegrino JR, Chief Financial Officer at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) executed a significant exercise of company stock options.
What Happened: A notable Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924006519//Archives/edgar/data/1158895/000143774924006519/0001437749-24-006519-index.htm">U.S. Securities and Exchange Commission</a> revealed that JR, Chief Financial Officer at LeMaitre Vascular, exercised stock options for 33,884 shares of LMAT, resulting in a transaction value of $1,075,673.
LeMaitre Vascular shares are trading, exhibiting down of 0.0% and priced at $67.92 during Tuesday's morning. This values JR's 33,884 shares at $1,075,673.
<h3>Delving into LeMaitre Vascular's Background</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>Understanding the Numbers: LeMaitre Vascular's Finances</h3>
Revenue Growth: LeMaitre Vascular displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 3.1%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 68.05%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, LeMaitre Vascular exhibits below-average bottom-line performance with a current EPS of 0.38.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: LeMaitre Vascular's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 50.7.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 7.87, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 29.12 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Sale: Joseph Pellegrino JR Decides To Exercise Options Worth $1.08M At LeMaitre Vascular

Barrington Research has decided to maintain its Outperform rating of LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) and raise its price target from $66.00 to $69.00.
Shares of LeMaitre Vascular are trading up 3.28% over the last 24 hours, at $64.15 per share.
A move to $69.00 would account for a 7.56% increase from the current share price.
<h3>About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Know

WIIM

LeMaitre Vascular shares are trading higher after the company reported better-than-expected Q4 GAAP EPS results and issued strong Q1 and FY24 guidance.

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $66 to $69.

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $69

Guidance

LeMaitre Vascular Sees Q1 EPS $0.36-$0.41 vs $0.34 Est., Sales $50.5M-$52.9M vs $50.21M Est.; Sees FY24 EPS $1.60-$1.71 vs $1.53 Est., Sales $209.7M-$214.3M vs $209.99M Est.

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
LeMaitre Vascular beat estimated earnings by 6.0%, reporting an EPS of $0.38 versus an estimate of $0.36.
Revenue was up $7.93 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 2.0% drop in the share price the next day.
Here's a look at LeMaitre Vascular's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.30</td>
<td>0.32</td>
<td>0.25</td>
<td>0.26</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.33</td>
<td>0.37</td>
<td>0.27</td>
<td>0.25</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>47.59M</td>
<td>48.29M</td>
<td>43.54M</td>
<td>40.99M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>47.41M</td>
<td>50.12M</td>
<td>47.08M</td>
<td>40.95M</td>
</tr>
</tbody>
</table>

To track all earnings releases for LeMaitre Vascular <a href="https://www.benzinga.com/quote/LMAT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: LeMaitre Vascular Q4 Earnings

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.36 by 5.56 percent. The company reported quarterly sales of $48.88 million which missed the analyst consensus estimate of $49.02 million by 0.28 percent. This is a 19.36 percent increase over sales of $40.95 million the same period last year.

Earnings Beats

Earnings Misses

LeMaitre Vascular Q4 2023 GAAP EPS $0.38 Beats $0.36 Estimate, Sales $48.88M Miss $49.02M Estimate

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.
Analysts estimate that LeMaitre Vascular will report an earnings per share (EPS) of $0.36. 
LeMaitre Vascular bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 2.45% drop in the share price the next day.
Here's a look at LeMaitre Vascular's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.30</td>
<td>0.32</td>
<td>0.25</td>
<td>0.26</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.33</td>
<td>0.37</td>
<td>0.27</td>
<td>0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>15.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708977706_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of LeMaitre Vascular were trading at $62.19 as of February 23. Over the last 52-week period, shares are up 23.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LMAT/earnings">To track all earnings releases for LeMaitre Vascular visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of LeMaitre Vascular's Earnings

Keybanc analyst Brett Fishbin initiates coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Sector Weight rating.

Keybanc Initiates Coverage On LeMaitre Vascular with Sector Weight Rating

On December 27, it was revealed in an SEC filing that George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) executed a significant exercise of company stock options.
What Happened: The latest Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774923035378//Archives/edgar/data/1158895/000143774923035378/0001437749-23-035378-index.htm">U.S. Securities and Exchange Commission</a> uncovered LeMaitre, Chairman and CEO at LeMaitre Vascular, exercising stock options for 16,446 shares of LMAT. The total transaction was valued at $350,753.
The Thursday morning update indicates LeMaitre Vascular shares down by 0.0%, currently priced at $57.67. At this value, LeMaitre's 16,446 shares are worth $350,753.
<h3>Unveiling the Story Behind LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
Revenue Growth: LeMaitre Vascular's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 21.48%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 65.0%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, LeMaitre Vascular exhibits below-average bottom-line performance with a current EPS of 0.34.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 47.3, LeMaitre Vascular's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.96, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 29.47, LeMaitre Vascular demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

George LeMaitre At LeMaitre Vascular Capitalizes: Options Exercised, Resulting In $350K

It was reported on December 11, that George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) executed a significant insider sell, according to an SEC filing.
What Happened: LeMaitre opted to sell 50,995 shares of LeMaitre Vascular, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774923034093//Archives/edgar/data/1158895/000143774923034093/0001437749-23-034093-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The transaction's total worth stands at $2,785,266.
As of Tuesday morning, LeMaitre Vascular shares are down by 0.0%, currently priced at $54.4.
<h3>About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>LeMaitre Vascular's Financial Performance</h3>
Revenue Growth: LeMaitre Vascular's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 21.48%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 65.0%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS reflects a decline, falling below the industry average with a current EPS of 0.34.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 44.59, LeMaitre Vascular's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.56, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 27.67, LeMaitre Vascular demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Transaction Codes To Focus On</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chairman and CEO At LeMaitre Vascular Sells $2.79M Of Stock

James John OConnor, Board Member at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>), reported a large exercise of company stock options on November 28, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774923033115//Archives/edgar/data/1158895/000143774923033115/0001437749-23-033115-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that OConnor, Board Member at LeMaitre Vascular, a company in the Health Care sector, just exercised stock options worth 7,500 shares of LMAT stock with an exercise price of $23.56.
LeMaitre Vascular shares are trading down 0.0% at $52.06 at the time of this writing on Wednesday morning. Since the current price is $52.06, this makes OConnor's 7,500 shares worth $390,450.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LeMaitre Vascular Board Member Acquires 7,500 Shares After Exercising Company Stock Options

George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>), reported a large exercise of company stock options on November 22, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774923032823//Archives/edgar/data/1158895/000143774923032823/0001437749-23-032823-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that LeMaitre, Chairman and CEO at LeMaitre Vascular, a company in the Health Care sector, just exercised stock options worth 12,747 shares of LMAT stock with an exercise price of $24.35.
LeMaitre Vascular shares are trading down 0.0% at $53.23 at the time of this writing on Wednesday morning. Since the current price is $53.23, this makes LeMaitre's 12,747 shares worth $678,522.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chairman and CEO at LeMaitre Vascular Exercises Options Worth $678K

Business Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Q4 2023 Guidance</td>
<td>Full Year 2023 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Sales</td>
<td>$48.0mm - $50.0mm (Mid: $49.0mm, +20%, +16% Org.)</td>
<td>$192.6mm - $194.6mm (Mid: $193.6mm, +20%, +17% Org.)</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>65.0%</td>
<td>64.9%</td>
</tr>
<tr>
<td>Op. Inc.</td>
<td>$9.4mm - $10.7mm (Mid: $10.0mm, +44%)</td>
<td>$35.9mm - $37.2mm (Mid $36.5mm, +36%)</td>
</tr>
<tr>
<td>Op. Inc. Ex-Special&#x2A;</td>
<td>-</td>
<td>$36.4mm - $37.7mm (Mid $37.0mm, +24%)</td>
</tr>
<tr>
<td>EPS</td>
<td>$0.34 - $0.38 (Mid: $0.36, +43%)</td>
<td>$1.30 - $1.35 (Mid: $1.33, +42%)</td>
</tr>
<tr>
<td>EPS Ex-Special&#x2A;</td>
<td>-</td>
<td>$1.32 - $1.36 (Mid: $1.34, +26%)</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;Special charges are related to the St. Etienne factory closure.

LeMaitre Vascular Sees Q4 EPS $0.34-$0.38 Vs $0.34 Est.; Revenue $48M-50M Vs $50.19M Est.; FY23 EPS $1.32-$1.36 Vs $1.28 Est. Revenue $192.6M-$194.6M Vs $195.01M Est.

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.30 by 10 percent. This is a 32 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $47.41 million which missed the analyst consensus estimate of $47.59 million by 0.38 percent. This is a 21.48 percent increase over sales of $39.03 million the same period last year.

LeMaitre Vascular Q3 EPS $0.33 Beats $0.30 Estimate, Sales $47.41M Miss $47.59M Estimate

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) has observed the following analyst ratings within the last quarter: 
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the last 3 months, 5 analysts have offered 12-month price targets for LeMaitre Vascular. The company has an average price target of $67.6 with a high of $75.00 and a low of $60.00. 
Below is a summary of how these 5 analysts rated LeMaitre Vascular over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1698080466_0.png" alt="price target chart" />
This average price target has increased by 6.74% over the past month.
<a href="https://www.benzinga.com/quote/LMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LeMaitre Vascular analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>How Are Analyst Ratings Determined?</h1>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This to Say About LeMaitre Vascular

JMP Securities analyst Daniel Stauder initiates coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Market Outperform rating and announces Price Target of $60.

JMP Securities Initiates Coverage On LeMaitre Vascular with Market Outperform Rating, Announces Price Target of $60

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kura Oncology (KURA – Research Report), Lemaitre Vas...

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Lemaitre Vascular (LMAT) and Agilon Health (AGL)

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report) today and set a price target of $70.00. The c...

Lemaitre Vascular (LMAT) Receives a Buy from Oppenheimer

LeMaitre Vascular raises dividend by 14.3% to $0.16

Michael Petusky, an analyst from Barrington, maintained the Buy rating on Lemaitre Vascular (LMAT – Research Report). The associated price target i...

Lemaitre Vascular's Strong Performance and Positive Outlook Justify Buy Rating

Lemaitre Vascular (LMAT) said after close Tuesday that it earned $0.38 per share in quarter four 2023. On the revenue line, the company reported $48.9 million, missing estimates by $137 thousand.In the same quarter a year ago, the company earned $0.25 per share on revenue of $41 million. The stock is up 10.36% to $68.55 af

Lemaitre Vascular Up 10.36% To $68.55 After Earnings Beat

Dividend Champion, Contender, And Challenger Highlights: Week Of March 3

39 Upcoming Dividend Increases Including 2 Dividend Kings

Dividend Champion, Contender, And Challenger Highlights: Week Of March 10

Markets Performance Review - February Dividend Income Report

Dividend Champion, Contender, And Challenger Highlights: Week Of March 24

AAPL

AGCO

ALLE

ALSN

AMAT

AMGN

AMSF

APLO

ARES

ATRI

AUBN

AVGO

AVNT

BANF

BCEFF

BCEIF

BCEPF

BCEXF

BCPPF

BECEF

BPOP

CABO

CADE

CASS

CBOE

CBSH

CCBG

CCFN

CCOI

CFFI

CGNX

CHRW

CINF

COFS

CPKF

CRAI

CSGS

CSWC

CTAS

CTBI